Selective endothelin receptor blockade in resistant hypertension: Results of the DORADO trial

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 1, 2011, Pages 153-155

  Grassi, Guido ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Blood pressure control; Darusentan; Endothelin receptor blocker; Resistant hypertension

Indexed keywords

DARUSENTAN; DIURETIC AGENT; PLACEBO;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FLUID RETENTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 78650486217     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.535812     Document Type: Article

References (6)

1. Calhoun DA, Jones D, Textor S, et al. & American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:510-26
2. Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009;361:932-4
3. Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010;56:1254-8
4. Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1423-31
5. Nakov R, Pfarr E, Eberle S, Heat Investigators. Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens 2002;15:583-9
6. Bakris GL, Lindholm LH, Black HR, et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010;56:824-30